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Corneal innervation is increasingly used as a surrogate marker of human diabetic peripheral
neuropathy (DPN) however its temporal relationship with the other microvascular complica-
tions of diabetes is not fully established. In this cross-sectional, observational study we
aimed to assess whether neuropathy occurred in patients with type 1 diabetes, without reti-
nopathy or microalbuminuria.
Materials and Methods
All participants underwent detailed assessment of peripheral neuropathy [neuropathy dis-
ability score (NDS), vibration perception threshold (VPT), peroneal motor nerve conduction
velocity (PMNCV), sural sensory nerve conduction velocity (SSNCV) and in vivo corneal
confocal microscopy (IVCCM)], retinopathy (digital fundus photography) and albuminuria
status [albumin: creatinine ratio (ACR)].
Results
53 patients with Type 1 diabetes with (n=37) and without retinopathy (n=16) were compared
to control subjects (n=27). SSNCV, corneal nerve fibre (CNFD) and branch (CNBD) density
and length (CNFL) were reduced significantly (p<0.001) in diabetic patients without retinop-
athy compared to control subjects. Furthermore, CNFD, CNBD and CNFL were also signifi-
cantly (p<0.001) reduced in diabetic patients without microalbuminuria (n=39), compared to
control subjects. Greater neuropathic severity was associated with established retinopathy
and microalbuminuria.
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Conclusions
IVCCM detects early small fibre damage in the absence of retinopathy or microalbuminuria
in patients with Type 1 diabetes.
Introduction
Diabetes and its complications represent a growing global health burden, affecting over an esti-
mated 366 million people worldwide [1]. The triad of retinopathy, nephropathy and neuropa-
thy are well recognised microvascular complications, and are the leading causes of premature
blindness, end-stage renal failure, foot ulceration and amputation, respectively [2]. Once estab-
lished, they have a major impact on the quality of life of patients with diabetes and are associat-
ed with adverse healthcare outcomes [3].
Diabetic retinopathy (DR) is strongly associated with nephropathy [4], and is one of the ear-
liest microvascular complications [5]. However, recent studies have shown that early neuronal
abnormalities, such as altered multi-focal electroretinogram (mfERG) responses [6], retinal
nerve fibre layer thinning [7] and loss of central visual field sensitivity [8] occur before the
onset of overt vascular lesions in the retina, and may be of prognostic value. Krolewski et al.
have previously found a strong association between cardiac autonomic neuropathy (CAN) and
proliferative DR (PDR) in patients with type 1 diabetes suggesting an underlying etiologic link
[9]. Indeed, the Rochester Diabetic Neuropathy Study has shown that markers of microvessel
damage such as DR and proteinuria or microalbuminuria (MA) are the strongest predictors
for the severity of DPN [10].
Recently, corneal nerve morphology assessed by IVCCM has been proposed as an early sur-
rogate marker for small nerve fibre damage in DPN [11, 12]. Furthermore, corneal nerve fibre
length correlates with clinical and electrophysiological measures of diabetic peripheral neuropa-
thy [13, 14] and long term glycaemic control [15, 16]. Recent studies have shown a stepwise de-
terioration in corneal nerve morphology in healthy subjects and patients with pre-proliferative
and PDR [17, 18]. The exact temporal relationship between neuropathy and retinopathy or ne-
phropathy however remains unclear. The purpose of this cross-sectional, observational study
was to establish whether neuropathy determined using the highly sensitive techniques of




80 subjects in total (53 with type 1 diabetes and 27 controls) were assessed in this study. Partici-
pants were excluded if they had a positive history of malignant, connective tissue or infectious
disease, deficiency of vitamin B12 or folate, chronic renal failure, liver failure, active diabetic
foot ulcers, family history of peripheral neuropathy. Participants were also excluded if they had
active ocular disease (except for DR), systemic disease known to affect the cornea other than di-
abetes or chronic corneal pathologies. Inclusion criteria for patients with diabetes mellitus were
a previous clinical diagnosis of type 1 diabetes, confirmed by laboratory biochemistry, and age
between 18–85 years old. Controls were confirmed not to have diabetes also by laboratory test-
ing and were of the same age range.
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Ethics Statement and data availability
This study adhered to the tenets of the Declaration of Helsinki and was approved by the North
Manchester Research Ethics Committee. Study subjects with diabetes were recruited from the
Manchester Diabetes Centre and control subjects were recruited from the community or were
relatives of the subjects with diabetes. Informed written consent was obtained from all subjects
prior to participation after explanation of the nature and possible consequences of the study.
The full, anonymised dataset can be found at https://researchdata.ands.orf.au/longitudinal-
assessment-neuropathy-markers-landmark/461294.
Clinical assessment
All study participants underwent assessment of HbA1c (%), lipid fractions [total cholesterol
(TC) (mmol/l), high (HDLC) and low density lipoprotein cholesterol (LDLC) (mmol/l), tri-
glycerides (mmol/l)] and albumin to creatinine ratio (ACR) (mmol/l).
Peripheral Neuropathy assessment
The modified neuropathy disability score (NDS) was assessed [19]. VPT was tested on the hal-
lux using a Neuroesthesiometer (Horwell, Scientific Laboratory Supplies, Wilfrod, Nottingham,
UK). Electro-diagnostic studies were undertaken using a Dantec “Keypoint” system (Dantec
Dynamics Ltd, Bristol, UK) and peroneal motor and sural sensory nerves [peroneal motor
nerve amplitude (PMNCV), sural sensory nerve amplitude (mV) and peroneal motor nerve
conduction velocity (PMNCV), sural sensory nerve conduction velocity (SSNCV) (m/s)] were
assessed in the left lower limb (calf-to-ankle) by a consultant neurophysiologist.
In-Vivo Corneal Confocal Microscopy
All study subjects were scanned with a laser IVCCM [Heidelberg Retinal Tomograph III Ros-
tock Cornea Module (Heidelberg Engineering GmbH, Heidelberg, Germany)]. This IVCCM
uses a 670 nm wavelength helium neon diode laser, which is a class I laser and therefore does
not pose any ocular safety hazard. A 63x objective lens with a numerical aperture of 0.9 and a
working distance, relative to the applanating cap (TomoCap©, Heidelberg Engineering GmbH,
Heidelberg, Germany) of 0.0 to 3.0 mm was used. The size of each two-dimensional image pro-
duced was 384 μm x 384 μmwhich has a 15° x 15° field of view and 10 μm/pixel transverse op-
tical resolution. This type of IVCCM uses an entirely digital image capture system and all
images are stored in an external hard drive.
A drop of 0.4% benoxinate hydrochloride (Chauvin Pharmaceuticals, Chefaro, UK) was
used to anaesthetise each eye and Viscotears (Carbomer 980, 0.2%, Novartis, UK) were used as
the coupling agent between the cornea and the applanating cap. All subjects were asked to fix-
ate on an outer fixation light throughout the IVCCM scan and a CCD camera was used to
image the cornea and correctly position the applanating cap onto the corneal apex. The overall
examination took approximately 5 minutes for both eyes of each subject and in this study two
experienced optometrists performed all IVCCM scans. All images were captured using the
“section” mode in the Heidelberg Explorer of the HRT III RCM. 5 to 8 images provide an ac-
ceptable level of accuracy to quantify the corneal subbasal nerve morphology [20]. We selected
and analysed 6 high clarity images/subject from the central subbasal nerve plexus. Criteria for
image selection were depth, focus position and contrast.
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Image Analysis
One examiner masked from cardiometabolic, peripheral neuropathy and retinopathy status
quantified subbasal nerve morphology in 480 images of all study participants, using semi-
automated, purpose-written, proprietary software (CCMetrics, M. A. Dabbah, Imaging Science
Biomedical Engineering, University of Manchester, Manchester, UK). The specific parameters
measured per frame were those we have previously established [12]: CNFD (no./mm2), CNBD
(no./mm2) and CNFL (mm/mm2). Specific details on the definition and measurement of each
parameter can be found elsewhere [21].
Study definition for retinopathy and nephropathy
The grade of retinopathy for patients with diabetes was defined as the most recent result (1 or
more examinations per annum) obtained from the UK NHS Diabetic Eye Screening Pro-
gramme (the full scope of the programme can be accessed here: http://diabeticeye.screening.
nhs.uk/service-specification), which is responsible for providing nationwide retinal screening
for patients with diabetes mellitus (the latest DR grading criteria as set by the Royal
College of Ophthalmologists can be found at:http://www.rcophth.ac.uk/news.asp?itemid=
1016&itemTitle=DIABETIC+RETINOPATHY+GUIDELINES+ADDED&section=
24&sectionTitle=News). Patients with “background retinopathy” or greater were classified as
“with retinopathy”. To rule out retinopathy in control subjects, a standard field fundus pho-
tograph was captured using a Canon CR-2 Plus digital, non-mydriatic retinal camera (Canon
Healthcare Technologies, Melville, New York, USA) and the image was graded by a study cer-
tified optometrist using the criteria proposed by the Early Treatment of Diabetic Retinopathy
Study [22]. To be eligible for the study, control subjects (determined by assessment of their
cardio-metabolic status and medical history) had to have a gradable ocular fundus image in
at least one eye. If signs of retinopathy were found the participant was informed and excluded
from the study. Albuminuria was determined using the albumin-to-creatinine ratio (ACR)
and microalbuminuria (MA) in this study was defined as an ACR>2.5 mg / mmol in males
and>3.5 mg / mmol in females. Similarly, control subjects with an abnormal ACR were in-
formed and excluded from the study.
Statistical analysis
Statistical analysis was performed using SPSS for Windows XP (Version 16.05.0, IBM, NY,
USA) and graphs were generated with OriginPro for Windows XP (Version 8.5.0 SR1, Origi-
nLab Corporation, Northampton, MA, USA). All data are expressed as mean ± SEM. Variables
were tested for normality by means of univariate analysis, histograms and the Shapiro-Wilk
test. One-way analysis of variance or non-parametric Kruskal Wallis was used to the test for
differences between the means. Post-hoc analysis (Tukey) was performed and after correction
for multiple testing (Bonferroni) a P<0.05 was considered significant.
Results
Clinical assessment
Detailed clinical and demographic results are presented in Table 1. Briefly, diabetic patients
(duration 28.6 ± 2.2 years) compared to control subjects had similar age (49.7 ± 2.1 v
49.7 ± 2.3, P>0.05) and BMI (27.0 ± 0.6 v 27.9 ± 0.9), higher HbA1c (%) (8.3 ± 0.3 v 5.6 ± 0.1,
P<0.001), a significantly lower TC (4.2 ± 0.2 v 5.2 ± 0.2, P<0.001), LDLC (2.1 ± 0.1 v 3.0 ± 0.1,
p<0.001), serum triglycerides (1.2 ± 0.1 v 1.7 ± 0.2, P<0.005) and comparable HDLC
(1.6 ± 0.2 v 1.5 ± 0.1, P>0.05).
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Neuropathy assessment
Detailed neuropathy results for patients stratified according to their retinopathy or microalbu-
minuria status are presented in Table 2.
Neuropathy vs. retinopathy
Patients without DR compared to control subjects showed a significantly lower CNFD
(P = 0.0001), CNBD (P<0.0001), CNFL (P<0.0001) and SNCV (P<0.05). There was a further
Table 1. Demographic results for study participants stratified according to retinopathy and nephropathy status.
Group Age T1D Duration
(Years)














49.7 ± 2.1 N/A 5.6 ± 0.1 27.9 ± 0.9 0.8 ± 0.1 5.2 ± 0.2 1.5 ± 0.1 3.0 ± 0.1 1.7 ± 0.2
Diabetes No DR
(n = 17)
43.5 ± 13.6 19.2 ± 4.0 8.0 ± 0.3† 26.5 ± 1.3 0.9 ± 0.2 4.3 ± 0.3† 1.5 ± 0.1 2.2 ± 0.3† 1.1 ± 0.2†
Diabetes DR
(n = 36)
52.3 ± 15.8‡ 32.7 ± 2.4‡ 8.4 ± 0.3† 27.1 ± 0.7 4.0 ± 1.4‡ † 4.1 ± 0.1† 1.6 ± 0.1 2.0 ± 0.2† 1.3 ± 0.1†
Diabetes No MA
(n = 39)
46.9 ± 2.9 25.7 ± 2.9 8.1 ± 0.2* 27.5 ± 1.8 0.9 ± 0.1 4.1 ± 0.2* 1.6 ± 0.1 2.0 ± 0.8* 1.1 ± 0.2*
DiabetesMA
(n = 14)
55.9 ± 4.8** 35.1 ± 4.2** 8.8 ± 0.8*
**
25.3 ± 1.4 6.1 ± 2.0*
**
4.3 ± 0.3* 1.6 ± 0.1 2.2 ± 0.8 1.3 ± 0.1*
Results are expressed as mean ± SEM. For patients with diabetes stratiﬁed according to retinopathy status:
† signiﬁcantly different from controls,
‡ signiﬁcantly different from “diabetes without DR”.
For patients with diabetes stratiﬁed according to albuminuria status:
* signiﬁcantly different from controls,
** signiﬁcantly different from “diabetes without MA”.
A P <0.05 was considered signiﬁcant.
doi:10.1371/journal.pone.0123517.t001
Table 2. Neuropathy measurements in controls and patients with Type 1 diabetes stratified according to retinopathy or microalbuminuria status.














Controls (n = 23) 0.4 ± 0.2 6.8 ± 1.1 16.4 ± 1.7 50.2 ± 0.8 5.4 ± 0.4 48.1 ± 0.6 37.1 ± 1.3 101.7 ± 7.4 27.7 ± 1.1
Neuropathy in patients with and without diabetic retinopathy
Diabetes No DR
(n = 17)
1.8 ± 0.7 8.7 ± 2.1 11.8 ± 1.5 45.9 ± 1.6 † 7.8 ± 3.1 44.8 ± 0.8 28.1 ± 2.3 † 56.1 ± 6.9 † 20.6 ± 1.5 †
Diabetes DR
(n = 36)
3.5 ± 0.5 † 17.7 ± 2.2 † 7.3 ± 1.0 † 42.3 ± 0.9 ‡ 3.3 ± 0.7
†
39.0 ± 1.2 † 22.1 ± 1.2 ‡ 49.9 ± 4.8 17.4 ± 0.9
Neuropathy in patients with and without microalbuminuria
Diabetes No MA
(n = 39)







5.5 ± 1.6 * 40.5 ± 1.7 * 1.8 ± 0.5 35.5 ± 2.4 * 17.3 ± 2.0 ** 37.9 ± 7.0 ** 14.3 ± 1.7 **
Results are expressed as mean ± SEM. For patients with diabetes stratiﬁed according to retinopathy status:
† signiﬁcantly different from controls,
‡ signiﬁcantly different from “diabetes no DR”.
For patients with diabetes stratiﬁed according to albuminuria status:
* signiﬁcantly different from controls,
** signiﬁcantly different from “diabetes no MA”.
A P <0.05 was considered signiﬁcant.
doi:10.1371/journal.pone.0123517.t002
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significant reduction in CNFD between patients with and without DR (P = 0.004) (Figs 1 and 2
and Table 2). There was an inverse correlation between the retinopathy grade and CNFD
(r = -0.67, P<0.001), CNBD (r = -0.58, P<0.001) and CNFL (r = -0.66, P<0.001).
Neuropathy vs. microalbuminuria
Diabetic patients without MA compared to control subjects had a significant reduction in
CNFD (P<0.0001), CNBD (P = 0.001) and CNFL (P<0.0001). There was a further significant
reduction for CNFD (P = 0.002), CNBD (P = 0.02), CNFL (P = 0.006) and PMNA (P<0.001)
in patients with MA (Fig 3 and Table 2).
Discussion
Diabetic microvascular complications result in considerable morbidity and both microalbu-
minuria and the severity of DR relate to the severity of DPN [10]. However, the temporal
Fig 1. Significant and progressive loss of CNFD (A) and CNFL (B) between controls, diabetic patients
‘without DR’ (n = 17) and ‘with DR’ (n = 36).Results are expressed as mean ± SEM.
doi:10.1371/journal.pone.0123517.g001
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relationship for the development of the microvascular complications has been systematically
assessed in very few studies. The United Kingdom Prospective Diabetes Study estimated the
prevalence of DPN, defined as loss of vibration perception, at ~7% [23], DR at 35–39% [24]
and MA at 7% at diagnosis of Type 2 diabetes [25]. In another population based study of
Fig 2. Fundus photograph of the central 30° with corresponding IVCCM image of the central subbasal
nerves (yellow arrows) for control (non-mydriatic) (CTR) (A) and patients with diabetes and varying
stages of DR (B, C and D). From left to right: (A) IVCCM image shows abundant corneal nerve axons for a
control without retinopathy, B) significant decrease of subbasal nerves in a patient with diabetes ‘without DR’
(No DR), C) slight progressive loss of subbasal nerves in a patient with diabetes and background DR (BDR)
and D) severe axonal loss on IVCCM in a patient with diabetes and pre-proliferative DR (PDR).
doi:10.1371/journal.pone.0123517.g002
Fig 3. Significant and progressive loss of CNFD (A) and CNFL (B) between controls, diabetic patients
‘without MA’ (n = 39) and ‘with MA’ (n = 14). Results are expressed as mean ± SEM.
doi:10.1371/journal.pone.0123517.g003
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newly diagnosed patients with Type 2 diabetes, DPN was present in 19%, retinopathy in
5% and nephropathy in 37%-48% [26]. A major limitation of these studies is the use of
variable definitions for neuropathy, which are subjective and lack sensitivity, and the use of
measures which detect neuropathy at an advanced stage compared to more standardized
measures of retinal and renal disease, which detect these complications at an earlier stage
of disease.
Over the past decade IVCCM has emerged as a novel non-invasive technique to identify
early neuropathy [11–14, 27]. The loss of corneal sub-basal innervation detected using IVCCM
correlates with peripheral nerve dysfunction, intra-epidermal nerve fiber [13] and retinal nerve
fiber layer [7] loss. Furthermore, neuroretinal abnormalities, such as altered mfERG response
waveforms, occur in the absence of retinopathy [6] and recently loss of central visual field sen-
sitivity has been related to the severity of DPN [8]. Importantly, prospective evaluation of
mfERG responses has shown that signal alterations can predict by precise location impending
retinal vasculopathy and/or edema. Previously, the Retinopathy in the Chronic Renal Insuffi-
ciency Cohort Study found a strong relationship between DR and urine protein concentration
but did not assess the relationship with DPN [4].
The present study shows that IVCCM detects a significant reduction in CNFD, CNBD and
CNFL in diabetic patients without DR. This is an important observation as it suggests that neu-
ropathy may precede detectable retinopathy, consistent with recent findings from other centres
[17, 18], but also that worsening of retinopathy from no DR to PDR is paralleled by further cor-
neal nerve loss and significant peripheral nerve dysfunction. Previously, a strong link has been
found between CAN and PDR [9]. Of pathophysiological relevance, retinal vessels are devoid
of sympathetic innervation and depend entirely on blood flow autoregulation, which has been
found defective even in diabetic subjects without retinopathy [28] and is further impaired with
increasing blood flow [29].
The present study also demonstrates a significant reduction in CNFD, CNFL and CNBD
and significant electrophysiological evidence of neuropathy in Type 1 diabetic patients ‘without
MA’, but the observed associations were less strong than with retinopathy, especially in sub-
jects ‘with MA’. Only 14 subjects were classified as having ‘MA’ compared to 36 ‘with DR’.
Moreover, these subjects with MA showed more marked alterations in electrophysiology, clini-
cal testing and IVCCM than those with DR. This suggests that incipient nephropathy may rep-
resent a relatively late microvascular complication, which occurs after significant neuropathy
and retinopathy have developed [30]. Furthermore, differences may be attributed to the use of
urine protein concentration, a measure of glomerular function as opposed to fundus photogra-
phy and IVCCM both measures of structural damage.
At present retinal photography and microalbuminuria are the endpoints of choice for
screening for retinopathy and nephropathy, respectively, and yet the monofilament test, a
quick bedside exam, is used for neuropathy screening. This study shows that significant small
nerve damage detected using IVCCM is detected in the absence of retinopathy and microalbu-
minuria. Therefore this challenges the current paradigm for screening strategies deployed to
detect the microvascular complications of diabetes. The identification of neuropathy using
IVCCMmay represent the earliest window of opportunity to intervene and prevent the pro-
gression of the triad of microvascular complications. A limitation of this study is the cross-
sectional design and the relatively small number of subjects studied. Another limitation is that
this study assessed only patients with type 1 diabetes and therefore results may not be directly
applicable to all patients with diabetes. However, two recent studies [17, 31] have demonstrated
similar findings in patients with type 2 diabetes. Future, prospective studies are needed to es-
tablish the exact temporal relationship between the development of neuropathy, retinopathy
and nephropathy, and to define the predictive value of IVCCM.
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